Beta Bionics Appoints Dr. Stephen Russell as Chief Medical Officer in Preparation for the Commercial Launch of the iLet Bionic Pancreas System

Beta Bionics, Inc.

Beta Bionics, Inc.

WARNING: The iLet Bionic Pancreas is an investigational system restricted by federal regulation for investigative use. Not out there on the market.

Stephen Russell

Stephen Russell

Stephen Russell

CONCORD, MA, Jan. 4, 2023 (GLOBE NEWSWIRE) — Beta Bionics, Inc. — a clinical-stage medical know-how firm — introduced the appointment of Stephen Russell, MD, to the place of Chief Medical Officer as the corporate prepares for the industrial launch of the iLet Bionic Pancreas System.

“As we strategy the industrial launch of iLet Bionic Pancreas, we’ve got strategically added a wealth of information and expertise to our govt crew,” defined Sean Saint, President and CEO of Beta Bionics. “Dr. Russell is a thought chief in diabetes know-how, and I’ve turned to him regularly over time for his expertise and perspective. His expertise with a robotic pancreas in a scientific setting is second to none. There isn’t any higher individual we may flip to for our Chief Medical Officer as we full the regulatory assessment course of and put together to launch iLet System in the US”.

Dr. Russell is an endocrinologist and diabetologist with 20 years of expertise in diabetes administration. He’s an assistant professor of medication at Harvard Medical Faculty and attending doctor at Massachusetts Common Hospital for Diabetes (MGH) in Boston, the place he has maintained a scientific observe for the outpatient and inpatient administration of diabetes. Dr. Russell’s analysis at MGH has centered on making use of new applied sciences to enhance diabetes care, together with collaborating with Dr. Ed Damiano’s analysis group at Boston College to develop and check a wearable digital pancreas for automated blood glucose management. in diabetes. Dr. Russell has directed almost the entire digital pancreas scientific trials, together with 20 research in sort 1 diabetes, sort 2 diabetes, and cystic fibrosis-related diabetes. He acquired a Bachelor of Science in Biochemistry from Trinity College in San Antonio and each have PhDs. in Organic Chemistry and MD from the College of Texas Southwestern Medical Heart in Dallas. He accomplished his coaching in inner drugs and a fellowship in endocrinology, diabetes, and metabolism at MGH, and a postdoctoral fellowship within the examine of insulin and growing older at Joslin Diabetes Heart in Boston.

“The Pancreas Important undertaking has been the main target of my skilled life for a few years. Till the completion of the pivotal trial, I felt I may convey probably the most worth to the undertaking as an educational doctor, advising and finishing up scientific trials,” mentioned Dr. Russell. “Now that the pivotal trial is full, I imagine my contributions shall be much more impactful by offering medical management inside Beta Bionics as we work in direction of FDA clearance and put together for iLet launch. I am excited to be part of the -star, and stay up for supporting individuals with diabetes and their healthcare suppliers. With the arrival of iLet from a analysis setting to scientific use.”

The iLet is a pocket-sized, investigative wearable medical system designed to independently dose insulin. It’s designed to be worn like an insulin pump, however iLet customers solely enter physique weight to begin therapy and don’t set any parameters for the insulin system. The iLet is designed to mechanically titrate and pump insulin with out requiring the person to calculate carbohydrates, set insulin-to-carbohydrate ratios, outline basal insulin charges, specify correction elements, or specify bolus insulin for meals or corrections. This know-how is designed to assist a large base of people that wish to use know-how to handle their diabetes.

“I’m delighted to welcome Stephen to Beta Bionics as our new Chief Medical Officer,” mentioned Ed Damiano, PhD, Founder and CEO of Beta Bionics. “I started collaborating with Stephen on the Pancreas Bioproject over 15 years in the past. Our partnership has spanned inpatient scientific trials, pre-pivotal home-use scientific trials, and most just lately, a pivotal trial of iLet in adults and youngsters with sort 1 diabetes. Merely put, it would not be The digital pancreas is simply as nice as it’s in the present day with out Stephen Russell. As a dad or mum of a son with T1D, I’m grateful for all he has carried out to advance this know-how and advocate for all individuals with T1D.”

Dr. Russell will preserve a college appointment at Harvard Medical Faculty and can proceed his medical observe part-time at MGH Diabetes Associates.

Warning: iLet Bionic Pancreas is an investigative system, pending 510(ok) elimination. Not out there on the market.

Contact info:
Stephen Feder
Monetary director and firm secretary

Karen Hines
Vice President of Advertising

Associated footage

Picture 1: Stephen Russell

This content material was launched by’s press launch distribution service.


Leave a Comment